NCT05822999 is a NA clinical trial of WELT-IP in Insomnia, sponsored by WELT corp.

Who is sponsoring NCT05822999?

NCT05822999 is sponsored by WELT corp.

What drugs are being tested in NCT05822999?

Interventions in NCT05822999: WELT-IP, Sham.

Is NCT05822999 still recruiting?

NCT05822999 is currently completed. Last updated 21 April 2023.

Last reviewed 2023-04-21 · How we verify

NCT05822999

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Efficacy of WELT-IP in Insomnia (WCTP-I-B-01)

Completed NA Last updated 21 April 2023

What this trial tests

NA trial testing WELT-IP in Insomnia in 52 participants. Completed in 8 June 2022.

Timeline

15 December 2021

Primary endpoint
26 April 2022

8 June 2022

Quick facts

Lead sponsor	WELT corp
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	52
Start date	15 December 2021
Primary completion	26 April 2022
Estimated completion	8 June 2022
Sites	1 location across South Korea

Drugs / interventions tested

WELT-IP
Sham

Conditions studied

Insomnia — all drugs for Insomnia →

Sponsor

WELT corp

Who can join

Adults 19 to 65, any sex, with Insomnia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study was to determine safety and efficacy of WELT-IP in adult insomnia patients. WELT-IP is a cognitive behavioral therapy for insomnia (CBT-I) based digital therapeutics.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Impact of Adherence to Digital Cognitive Behavioral Therapy for Insomnia Effectiveness.
Lee S, Park KM, Lee DH, Choi EC, et al · · 2025 · cited 1× · PMID 40992766 · DOI 10.3349/ymj.2024.0398
Culturally adapted digital cognitive behavioral therapy for insomnia in South Korea - a double-blind randomized controlled trial.
Kabbani A, Passler M, Park K, Lee E, et al · · 2026 · PMID 41883996 · DOI 10.1016/j.invent.2026.100933

Verify or expand the search:

Other trials of WELT-IP

Trials testing the same drug.

NCT05809544 — Study of Efficacy of WELT-IP in Insomnia (WCTP-I-B-02) · NA · completed

Other recruiting trials for Insomnia

Currently open trials in the same condition.

NCT07384429 — Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease · Phase 4 · recruiting
NCT07270406 — Healthy Behaviors for Insomnia Prevention in People With HIV and Ongoing Pain · NA · recruiting
NCT07071324 — CF Wellness Program · NA · recruiting
NCT07417813 — A Multicenter Observational Study of Lemborexant on Insomnia Patients With Psychiatric Disorders · recruiting
NCT06348082 — Project Women's Insomnia Sleep Health Equity Study (WISHES) · NA · recruiting

Other WELT corp trials

Trials by the same sponsor.

NCT06294353 — Study of Efficacy and Safety of WELT-ED for Eating Disorder (WCTP-ED-B-01) · NA · unknown
NCT05809544 — Study of Efficacy of WELT-IP in Insomnia (WCTP-I-B-02) · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05822999 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by WELT corp
Last refreshed: 21 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05822999.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing